MedTrace Logo

Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

NCT04885634 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-11-03

No results posted yet for this study

Summary

The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.

Conditions

Interventions

DRUG

Semaglutide Injectable Product

Subcutaneous injection of Semaglutide 2.4 mg once weekly

DRUG

Placebo

Subcutaneous injection of volume-matched placebo once weekly

Sponsors & Collaborators

  • Herlev and Gentofte Hospital

    collaborator OTHER

  • Hillerod Hospital, Denmark

    collaborator OTHER

  • Svendborg Hospital

    collaborator OTHER

  • Esbjerg Hospital - University Hospital of Southern Denmark

    collaborator OTHER

  • Axel Brandes

    lead OTHER

Principal Investigators

  • Axel Brandes, MD, DMSc · Odense University Hospital

  • Morten L Hansen, MD, PhD · Herlev and Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2024-01-31
Completion
2024-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885634 on ClinicalTrials.gov